ETCTN 10388 trial: what clinicians have said so far
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
- NCT04234568 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on ETCTN 10388 (triapine plus lutetium-177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ETCTN 10388 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 12 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Neuroendocrine Tumor
- Interventions
- Biospecimen Collection; Computed Tomography; Lutetium Lu 177 Dotatate; Magnetic Resonance Imaging; Triapine
- Arms
- Treatment (lutetium Lu 177 dotatate, triapine) · Experimental
- Enrollment
- 31
- Primary outcomes
- Maximum Tolerated Dose (MTD) of Triapine and Recommended Phase 2 Dose (RP2D)
- Dose Limiting Toxicity (DLT)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 20, 2020
- Primary completion
- Sep 17, 2024
- Results posted
- Yes
- Registry record
- NCT04234568 · updated Sep 18, 2026
Publications
linked from the registry- Chauhan A, Weiss HL, Kunos C, Jayswal R, Konda B, Soares HP, Li D, Halfdanarson TR, Mulcahy MF, Jacene HA, Khurana A, Modak R, Yan D, Beumer JH, Christner SM, Wu PI, Das B, Rubinstein LV, Gore SD, Ivy SP, Kohn EC, Carson WE, Anthony LB, Arnold SM. Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388). Clin Cancer Res. 2026 Jul 28. doi: 10.1158/1078-0432.CCR-26-0686. Online ahead of print. PubMed 42518206